CareStart COVID-19
Rapid Antigen Test


The CareStart COVID-19 Rapid Antigen Test is provided by
Gingko BioWorks and created by device manufacturer Access Bio. With results that are read at 10 minutes, this solution is enabled with digital reporting.

Results available onsite, no need for long waits

Accurate and reliable, meeting all FDA requirements for sensitivity, specificity and accuracy

Simple to launch,
we do the heavy lifting

so you can test more often


The CareStart COVID-19 Rapid Antigen Test* is digitally enabled with Everlywell Lens, helping organizations:

*CLIA Waiver ID number must be provided before testing can begin 

View, sort and filter test results as they become available, alerting them of positive results.

Automatically transmit test results to appropriate agencies using a HIPAA-compliant interface.

Search individual test results in instances where negative results are required for entry.

An ideal solution for organizations looking to accurately test quickly, frequently and at a low cost.


Schools and Universities

Local Governments



Digital results for organizations and participants in 9 simple steps



The participant registers their test and answers a few required questions.


The participant hands their registration card to the healthcare provider responsible for administering the test.

At your organization’s CLIA Waived collection event, the participant is given a registration card with a unique ID.


The healthcare provider confirms the participant’s information in Everlywell Lens, the digital platform for viewing and sorting test results.


The healthcare provider administers the test with the nasopharyngeal or anterior nasal collection method.


The participant is free to leave the collection event.


Result is read at 10 minutes and the healthcare provider enters it into Everlywell Lens.


The participant is notified by text notification or email of their result.


The organization tracks all results in Everlywell Lens. 

 The CareStart COVID-19 Rapid Antigen Tests are only authorized for point-of-care use by qualified healthcare professionals

This disposable rapid antigen lateral flow device will be used under the supervision of a healthcare professional with the nasopharyngeal or anterior nasal collection method.

Request a demo to see how your organization can implement a digitally-enabled COVID-19 rapid testing solution.

CareStart COVID-19 Rapid Antigen Test Resources:
EUA, Fact Sheet for Providers, Fact Sheet for Patients and IFU

This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories;  

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and  

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.




 © 2020 Everlywell, Inc. All rights reserved.